


Molecule of the Month

**CERC-501 (A3028)**



For this month's MOTM we are going to highlight CERC-501.

CERC-501 (A3028, originally known as LY-2456302) is a selective antagonist of the  $\kappa$ -opioid receptor (KOR) which was originally developed by Eli Lilly and is now under development by Janssen Pharmaceuticals for the treatment of major depressive disorder and substance use disorders including alcoholism, nicotine addiction, and illicit drug dependence. CERC-501 has reached phase II clinical trials as an augmentation to antidepressant therapy for treatment-resistant depression.

Should you require analogues of these molecules to support your research activities don't hesitate to get in touch with us. Alternatively, if you would like to explore our complete range of products and services or require any further information regarding LCC, please use the enquiry button at the top of our webpage to get in touch.

